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OBJECTIVE
To assess the safety and efficacy of dual sodium–glucose cotransporter (SGLT) 1
and SGLT2 inhibition with sotagliflozin as adjunct therapy to insulin in type 1
diabetes.
RESEARCH DESIGN AND METHODS
We treated 33 patients with sotagliflozin, an oral dual SGLT1 and SGLT2 inhibitor,
or placebo in a randomized, double-blind trial assessing safety, insulin dose,
glycemic control, and other metabolic parameters over 29 days of treatment.
RESULTS
In the sotagliflozin-treated group, the percent reduction from baseline in the
primary end point of bolus insulin dose was 32.1% (P = 0.007), accompanied by
lower mean daily glucose measured by continuous glucose monitoring (CGM)
of 148.8 mg/dL (8.3 mmol/L) (P = 0.010) and a reduction of 0.55% (5.9 mmol/mol)
(P = 0.002) in HbA1c compared with the placebo group that showed 6.4% reduction in
bolus insulin dose, a mean daily glucose of 170.3 mg/dL (9.5 mmol/L), and a decrease
of 0.06% (0.65 mmol/mol) in HbA1c. The percentage of time in target glucose range
70–180 mg/dL (3.9–10.0 mmol/L) increased from baseline with sotagliflozin com-
pared with placebo, to 68.2% vs. 54.0% (P = 0.003), while the percentage of time in
hyperglycemic range>180mg/dL (10.0mmol/L) decreased frombaseline, to 25.0%vs.
40.2% (P = 0.002), for sotagliflozin and placebo, respectively. Body weight decreased
(1.7 kg)with sotagliflozin comparedwith a 0.5 kg gain (P = 0.005) in the placebo group.
CONCLUSIONS
As adjunct to insulin, dual SGLT1 and SGLT2 inhibition with sotagliflozin improved
glycemic control and the CGM profile with bolus insulin dose reduction, weight
loss, and no increased hypoglycemia in type 1 diabetes.
Therapy for type 1 diabetes has advanced considerably since the historic publication
of the Diabetes Control and Complications Trial (1) in 1993 with the introduction of
new fast-acting and basal insulin analogs, more accurate blood glucose meters,
smaller and more technically advanced insulin pumps, and the availability of con-
tinuous glucose monitoring (CGM). Despite these advances, sustained improve-
ments in glycemic control are still associated with hypoglycemia and severe
hypoglycemia (SH). The 12-month risk of SH associated with seizure or loss of
consciousness was recently reported at 11.6% in adults and 9.9% in youth, rising
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to 18.6% in adults with type 1 diabetes
for.40years (2,3). The cause of death for
individuals with type 1 diabetes has been
examined in several longitudinal studies,
indicating that between 4 and 10% of
deaths can be attributed to hypoglycemia
(4–7), providing a stark reminder of the
risks of tight glycemic control with insulin
alone. Recent data also indicate that ap-
proximately one-third of patients are
worried about hypoglycemia and a similar
proportion purposelymaintain a hypergly-
cemic state seeking a “safetymargin” from
hypoglycemia (8). Additionally, ;30% of
patients with type 1 diabetes in the U.S.
are obese (9,10) and ;50% of patients
have metabolic syndrome (11). There is a
clear need for the development of new
adjunct therapies to insulin that can im-
prove glycemic control in this population
without weight gain or an increase in the
risk of hypoglycemia.
Highly selective inhibitors of sodium–
glucose cotransporter (SGLT) 2, the
transporter primarily responsible for re-
nal glucose reabsorption, are approved
for the treatment of type 2 diabetes (12)
and under exploration in patients with
type 1 diabetes (13–15). SGLT1 is the
primary transporter for absorption of
glucose and galactose in the intestine
(16). Sotagliflozin is a novel, orally de-
livered, small-molecule dual inhibitor
of SGLT1 and SGLT2 that was designed
to reduce glucose absorption in the gas-
trointestinal (GI) tract via SGLT1 inhibi-
tion and renal glucose reabsorption via
SGLT2 inhibition (17). Sglt1 knockout
mice given a meal challenge containing
glucose exhibit decreased blood glucose,
increased delivery of glucose to the distal
small intestine and cecum, and increased
GLP-1 release indicating a potential utility
for inhibition of intestinal SGLT1 (18,19).
Homozygous knockout mice maintained
on a diet containing glucose and galac-
tose also exhibit unformed watery stools,
decreased food intake, and reduced
weight, findings consistent with glucose
and galactose malabsorption, a condition
characterized by severe diarrhea, in in-
fants with mutations in SGLT1 (16). With
this inmind, most pharmaceutical discov-
ery programs focused on selective SGLT2
inhibitors to avoid potential GI side ef-
fects. However, heterozygous Sglt1
knockout mice also exhibit increased de-
livery of glucose to the distal small intes-
tine and cecum and increased GLP-1
release after a glucose-containing meal
challenge but have normal stools, nor-
mal food intake, and normal weight
gain when maintained on a diet contain-
ing glucose and galactose (18). Addition-
ally, it has been reported that most
individuals in a large family cohort of pa-
tients with galactose malabsorption at
birth could tolerate a normal diet by
the age of 20 years, suggesting that se-
vere reduction in SGLT1 activity is com-
patiblewith relatively normal GI function
(20). These data were consistent with a
“window” for achieving glycemic efficacy
with potent SGLT2 inhibition and partial
SGLT1 inhibition, thereby avoiding the GI
side effects of complete SGLT1 inhibi-
tion. Sotagliflozin fulfilled these criteria
with 20-fold selectivity for SGLT2 over
SGLT1 with SGLT2 half-maximal inhibi-
tory concentration of 0.0018 mmol/L
and SGLT1 half-maximal inhibitory con-
centration of 0.036 mmol/L (17).
Inhibiting SGLT1, the major intestinal
glucose transporter, holds promise to
improve glucose control by reducing
postprandial glucose peaks and stimu-
lating release of GI peptides, such as
GLP-1 and polypeptide tyrosine tyrosine
(PYY) (18,19,21), that assist in glycemic
and appetite control (22,23). Preclinical
and clinical studies conducted to date
have confirmed the effects of sotagliflo-
zin on postprandial glucose, GLP-1, and
PYY (17–19,24,25). In patients with type
2 diabetes, sotagliflozin treatment low-
ered HbA1c, reduced body weight, and
lowered blood pressure with a low risk
of hypoglycemia (17,26). In a dose-ranging
study in patients with type 2 diabetes
inadequately controlledwithmetformin,
HbA1c reduction nearly doubled as sota-
gliflozin dose increased in the absence of
additional increases in urinary glucose
excretion (UGE) supporting meaningful
intestinal SGLT1 inhibition (26). In a re-
cent study in patients with type 2 diabetes
and moderate to severe renal impairment
(estimated glomerular filtration rate 15–59
mL/min/1.73 m2), sotagliflozin produced a
significant decrease in PPG excursion
and an increase in GLP-1 secretion (27).
This difference was preserved in the pa-
tient subgroup with more severe renal
impairment despite the expected reduc-
tion of UGE suggesting that, unlike the
effects of SGLT2 inhibition, the effects of
intestinal SGLT1 inhibition are main-
tained as kidney function declines.
We hypothesized that in type 1 diabe-
tes, sotagliflozin would improve glycemic
control while concomitantly simplifying
the insulin regimen without weight gain.
In contrast to selective SGLT2 inhibitors,
the additional inhibition of SGLT1 by sota-
gliflozin was predicted to lower postpran-
dial glycemic excursions and decrease
bolus insulin, thereby lowering the poten-
tial for postprandial hypoglycemia. Here,
we present the results of a randomized,
multicenter, placebo-controlled, double-
blind evaluation of sotagliflozin treatment
in adults with inadequately controlled type
1 diabetes as adjunct therapy to usual in-
sulin delivery method: either continuous
subcutaneous insulin infusion (CSII) or




This study was a randomized, multicenter,
placebo-controlled, double-blind evalua-
tion of sotagliflozin in adult patients with
type 1 diabetes using their previous insulin
delivery regimen: either CSII or MDI. The
study design is presented in Fig. 1.
The study was initiated with an open-
label pioneer group (n = 3) on CSII to es-
tablish preliminary safety and to provide
information on insulin dose adjustment
during initiation of treatment. Subsequent
to completion of treatment of the pioneer
group, patients on either MDI or CSII were
enrolled in the placebo-controlled portion
of the study and randomly assigned 1:1,
using an interactive web response system,
to receive, in a double-blind fashion,
either a total daily dose of 400 mg sotagli-
flozin or placebo taken within 15min prior
to breakfast for 29 days.
The initial 7 days (days27 to21) of the
study were used to obtain baseline labo-
ratory samples, to record baseline insulin
doses through use of daily diaries, and to
obtain at least 3 days of blinded CGMdata
on an outpatient basis during patients’
usual insulin, dietary, and activity regi-
men. Days 1 and 2 of the study were con-
ducted in an inpatient setting to allow
supervision of initial insulin dose adjust-
ments and to obtain multiple pharmaco-
kinetic (PK) and pharmacodynamic (PD)
samples. The first treatment dose (day
1) was administered before a mixed-
meal tolerance test (MMTT) prior to
breakfast with no bolus insulin adminis-
tered. Basal insulin was continued un-
changed. Subsequently, investigators
adjusted the suggested dosage of short-
acting insulin at each meal with guidance
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from an algorithm based on treat-
to-target blood glucose goals consistent
with current standard of care (fasting
and preprandial: 80–130 mg/dL [4.4–7.2
mmol/L], postprandial: ,180 mg/dL [10
mmol/L], and bedtime/overnight: 100–
180 mg/dL [5.6–10 mmol/L]). On day 2,
patients were discharged and insulin
doseswere to be adjusted as determined
by the patient and investigator assess-
ment of scheduled self-monitoring of
blood glucose (SMBG). With standard
American Diabetes Association dietary
recommendations, patients were in-
structed to resume their regular rou-
tines. Blinded CGM data were collected
on all patients throughout the studywith
the Enlite subcutaneous glucose sensor
(Medtronic, Inc., Northridge, CA). On day
28, patients returned to inpatient for
;36 h for end-of-treatment MMTT
(with usual insulin dosing) and to obtain
multiple PK and PD samples; patients
were then discharged and followed for
an additional week.
Study Outcomes
The primary outcome of the study was
the treatment effect on change from
baseline of total daily bolus insulin
dose during the outpatient treatment
period. The secondary outcomes per-
tained to specifics of insulin use includ-
ing change from baseline of total daily
bolus insulin at each meal, total daily
basal insulin, and total daily bolus plus
total daily basal insulin. The secondary
outcomes pertaining to glycemic control
included assessing the effect of sotagli-
flozin on fasting plasma glucose (FPG)
and glucose excursion during the 3-h pe-
riod after anMMTT asmeasured by area
under the curves (AUCs). Secondary out-
comes associated with CGM included
percent time in defined ranges, 1) ,70
mg/dL (3.9 mmol/L) and $70 mg/dL (3.9
mmol/L) and #180 mg/dL (10.0 mmol/L)
and 2) .180 mg/dL (10.0 mmol/L) and
.250 mg/dL (13.9 mmol/L), as well as
changes in mean daily interstitial glucose.
Additional measures of glucose variability
were included as secondary outcomes in-
cluding coefficient of variation;meanSDof
weekly glucose level; mean amplitude of
glucose excursion (MAGE), defined as the
average of all glucose excursion that ex-
ceeded 1 SD over each 24-h period, as de-
scribed by Baghurst (28); low blood
glucose index; and high blood glucose in-
dex (HBGI). Exploratorymeasures included
the effect of sotagliflozin treatment on
HbA1c as well as changes in GLP-1, PYY,
C-peptide, and UGE over a 3-h post–
breakfast MMTT.
Assessments of safety included vital
signs, electrocardiograms, and laboratory
parameters (chemistry, hematology, lipid
profiles, and urinalysis). Safety and toler-
ability of sotagliflozin were assessed by
collection and review of adverse events,
which were followed until resolution. Ad-
verse events of special interest in this
study included urogenital infections and
hypoglycemia.
Study Oversight
The human research committees and/or
institutional review boards of participat-
ing investigative sites approved the pro-
tocols, and all patients provided written
informed consent.
Statistical Analysis
The intent-to-treat population was com-
prised of all randomized patients in the
placebo controlled expansion group. Anal-
yses using this population served as the
primary population for statistical analyses
and reporting. The PK population included
all patients who received at least one dose
of study drug and had sufficient, valid PK
samples to estimate key parameters for at
least one of the days of sampling. Pharma-
cokinetic summarieswere basedon the PK
population. The safety population in-
cluded all patients who were randomized
and received$1 dose of study drug.
RESULTS
Patients
A total of 36 patients were enrolled in
the study between 8 February and 20
November 2013, with 3 patients in the
open-label pioneer group and 33 patients
in the randomized, placebo-controlled,
double-blindcohort.Results for thepioneer
group were used to evaluate safety and in-
form the insulin-adjustment paradigm for
thedouble-blindportionof the study. Base-
line characteristics of the patients are
shown in Table 1. Patient disposition is
summarized in Supplementary Fig. 2.
Figure 1—Study design.
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Outcomes
Bolus Insulin
The percent change from baseline in to-
tal daily bolus insulin use was232.0% in
the sotagliflozin group and26.4% in the
placebo group (P = 0.007) (Tables 2 and 3).
Given that sotagliflozin was adminis-
tered once daily before breakfast, a pre-
specified subgroup analysis of bolus
insulin use before major meals was con-
ducted to detect differences throughout
the day. Reductions of bolus insulin from
baseline before each meal were noted in
patients treated with sotagliflozin com-
paredwith placebo:228.4% vs. 13.6% at
breakfast (P = 0.046),225.9% vs. 7.1% at
lunch (P = 0.08), and 223.8% vs. 39.3%
at dinner (P = 0.052) (Table 3). The ef-
fects of sotagliflozin on bolus insulin
requirements were similar whether pa-
tients were on MDI or CSII.
Basal Insulin and Total Daily Insulin
The use of basal insulin was similar be-
tween the groups, and the change from
baseline for both groups was minimal.
There was a numerical decrease from
baseline of 2.4% for the sotagliflozin
group compared with a numerical in-
crease from baseline of 0.2% in the pla-
cebo group (P = 0.53, Tables 2 and 3).
Total daily insulin was lower for the so-
tagliflozin group, with a reduction from
baseline of 15.3% (P = 0.002) and a re-
duction of 0.7% for the placebo group
(P = 0.029, difference between groups)
(Tables 2 and 3).
Glucose Levels by CGM
Over the outpatient treatment period,
sotagliflozin therapy resulted in a lower
mean daily glucose asmeasured by CGM
(Supplementary Fig. 1) of 148.8 mg/dL
(8.3 mmol/L) compared with a placebo
value of 170.3 mg/dL (9.5 mmol/L) (P =
0.010) (Table 3). In addition, patients in
the sotagliflozin treatment group
spent a greater percentage of time in
the target glycemic range defined as
$70 mg/dL (3.9 mmol/L) and #180
mg/dL (10.0 mmol/L) compared with
placebo (68.2% vs. 54.0%, P = 0.003)
(Table 3 and Supplementary Fig. 1),
while percentage of time spent in the
hyperglycemic range, .180 mg/dL
(10.0 mmol/L), was lower compared
with placebo (25.0% vs. 40.2%, P =
0.002) (Table 3 and Supplementary Fig.
1), as was percentage of time spent
.250 mg/dL (13.9 mmol/L) (6.7% vs.
14.1%, P, 0.008) (Table 3). The sotagli-
flozin and placebo groups exhibited a
similar percentage of time spent in the
hypoglycemic ranges of,70 mg/dL (3.9
mmol/L) (6.7% vs. 5.8%, P = 0.80) (Table
3 and Supplementary Fig. 1).
After meals, sotagliflozin treatment
produced favorable effects on postpran-
dial glycemic excursions as assessed by
CGM during a 3-h period. In the sotagli-
flozin group, mean change from baseline
at breakfast was 216.7 mg/dL (20.93
mmol/L) vs.24.2 mg/dL (20.23 mmol/L)
(P = 0.034) (Supplementary Table 2).
The changes from baseline at lunch and
dinnerwere numerically lower for sotagli-
flozin than placebo but did not reach
statistical significance.
Notably, therewas less glucose variabil-
ity on sotagliflozin treatment asmeasured
by MAGE, calculated as 120.8 mg/dL (6.7
mmol/L) for the sotagliflozin treatment
group, compared with 145.5 mg/dL (8.1
mmol/L) for placebo (P = 0.041) (Table
3). CGMSDwas also lower on sotagliflozin
treatment, calculated as 50.0 for the sota-
gliflozin treatment group compared with
58.8 for placebo (P = 0.022) (Table 3). Con-
sistent with the percentage of time spent
in hyperglycemic ranges, the mean HBGI
was reduced from baseline in the sotagli-
flozin group compared with an increase in
the placebo group (P = 0.006) (Table 3).
HbA1c
There was a significant decrease in HbA1c
of 0.55% (5.9 mmol/mol) from baseline
after 29 days of treatment with sotagliflo-
zin comparedwith0.06% (0.65mmol/mol)
for the placebo group (P = 0.002) (Table 2).
The effects of sotagliflozin on HbA1c were
similar whether patients were on MDI or
CSII.
Hypoglycemia
Total hypoglycemic events defined as
SMBG #70 mg/dL (3.9 mmol/L) in the
placebo group numbered 354. Of these,
185 (52%) were symptomatic and 117
(33%) were asymptomatic. In the sota-
gliflozin treatment group, the total num-
ber of events was 304. Of these, 162
events (53%) were symptomatic and
80 events (26%) were asymptomatic.
There were no SH events in either group.
Hypoglycemic events per patient per day
(PPD), defined as SMBG #70 mg/dL (3.9
mmol/L), declined significantly from base-
line during treatment in both groups, and
in both groups hypoglycemia PPD was 0.4
(Table 2). Hypoglycemic events PPD, by
blinded CGM (defined as$10 continuous
minutes of glucose readings ,70 mg/dL
Table 1—Demographic characteristics (intent-to-treat population)
Patient characteristics Placebo (N = 17) Sotagliflozin (N = 16)
Age (years), median (range) 34.0 (21, 57) 45.5 (21, 55)
Sex, n (%)
Female 9 (53) 8 (50)
Male 8 (47) 8 (50)
Race, n (%)
White/Caucasian 14 (82) 16 (100)
Asian 2 (12) 0
Other 1 (6) 0
Weight (kg), median (range) 72.7 (55.3, 104.6) 74.2 (55.6, 107.9)
BMI (kg/m2), mean (SD) 26.2 (3.0) 27.1 (3.1)
Duration of diabetes (years), median (range) 18.5 (4.7, 40.8) 16.8 (3.4, 42.9)
HbA1c (%), mean (SD) 7.98 (0.51) 7.94 (0.55)
HbA1c (mmol/mol), mean (SD) 62.83 (5.66) 63.38 (6.04)
FPG (mmol/L), mean (SD) 8.89 (3.96) 9.45 (3.45)
Seated systolic BP (mmHg), mean (SD) 119.8 (7.0) 118.1 (9.2)
Serum sodium (mmol/L), mean (SD) 138.24 (3.75) 137.63 (2.45)
Serum creatinine (mmol/L), mean (SD) 76.11 (9.86) 76.94 (11.82)
Serum BUN (mmol/L), mean (SD) 4.68 (0.99) 4.96 (1.02)
Hematocrit, mean (SD) 41.94 (4.87) 41.63 (4.86)
Insulin therapy, n (%)
MDI 5 (29) 6 (38)
CSII 12 (71) 10 (63)
Total daily insulin (IU/kg), mean 0.60 0.60
Daily insulin, ratio of bolus/total 0.45 0.49
BP, blood pressure.
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(3.9 mol/L), declined numerically during
treatment in both groups.
Body Weight, PYY, Urinary Glucose, and
Other Outcomes
Mean body weight decreased with sota-
gliflozin treatment compared with an in-
crease in the placebo group (21.7 kg vs.
0.5 kg) (P = 0.005) (Table 2). Change from
baseline AUC after a meal challenge for
PYY was increased by 6.0 pmol/L z h over
3 h in the sotagliflozin group and de-
creased by 0.7 pmol/L z h over 3 h with
placebo (P = 0.018) (Table 2).
An MMTT performed on the last
treatment day of the study showed a
lower serum glucose 3-h AUC in the so-
tagliflozin group compared with placebo
(595 mg z h/dL vs. 761 mg z h/dL, respec-
tively, P = 0.009) (Table 2). The mean 3-h
UGE was higher in the sotagliflozin group
compared with placebo (29.1 g/3 h vs.
9.2 g/3 h, respectively, P = 0.025) (Table 2).
Systolic blood pressure decreased in both
groups, with a decline of 4.9 mmHg in the
sotagliflozin-treated group and a decline
of 3.9 with placebo (P = 0.45) (Table 2).
Laboratory values associated with volume
status (serum sodium, serum creatinine,
serum BUN [blood urea nitrogen], and
hematocrit) were assessed at baseline,
the last day of therapy (day 29), and 1
week after last dose of study medication
(day 36). In the sotagliflozin group, there
were numeric increases in most values,
which returned toward baseline at day
36, consistent with reversible perfusion
and volume effects. There were no
meaningful changes in other exploratory
end points including stimulated C-peptide,
C-reactive protein, triglycerides, and uric
acid (data not shown).
Adverse Events
Fourteen (88%) patients on sotagliflozin
reported adverse events compared with
12 (71%) patients on placebo. No ad-
verse events led to discontinuation
from the study. The most frequently re-
ported treatment-emergent adverse
events (TEAEs) in the sotagliflozin group
by MedDRA System Organ Class were GI
disorders, eight sotagliflozin patients
(50%) compared with three placebo pa-
tients (18%), with the most notable im-
balance being three reports of nausea
on sotagliflozin versus one on placebo.
Treatment differences in incidence of
TEAEs were not statistically tested. TEAEs
are summarized in Supplementary Table 1.
Two serious adverse events of diabetic
ketoacidosis were reported in two pa-
tients using insulin infusion pumps and
treated with sotagliflozin. Both cases of
DKA were assessed by the investigators
as pump related and were not related
to the study drug. Details of the events
are provided in Supplementary Table 1.
CONCLUSIONS
We evaluated dual inhibition of SGLT1
and SGLT2 using sotagliflozin as adjunct
to insulin in inadequately controlled
type 1 diabetes in a double-blind, pla-
cebo-controlled trial over 29 days. Dur-
ing the study period, patients continued
their usual insulin delivery regimens
while attempting to achieve American
Diabetes Association–recommended
glucose targets goals and maintaining
their usual activity levels and diet. Treat-
ment with 400 mg sotagliflozin given
once daily before breakfast resulted in
significant reductions in bolus insulin
Table 2—Overall summary of results
Placebo (N = 17) Sotagliflozin (N = 16) P
Efficacy
HbA1c change from baseline (%) 20.06 20.55* 0.002
FPG change from baseline assessed at day 29 (mg/dL) 39.0 218.6 0.15
Daily bolus insulin change from baseline assessed at days 3–27 (%) 26.4 232.0* 0.007
Daily basal insulin change from baseline assessed at days 3–27 (%) 0.2 22.4 0.53
Total daily insulin change from baseline assessed at days 3–27 (%) 20.7 215.3* 0.029
Mean body weight change from baseline assessed at day 29 (kg) 0.5 21.7* 0.005
Postmeal urinary glucose (g/3 h) at day 29† 9.2 29.1 0.025
Postmeal plasma glucose AUC (mg z h/dL over 3 h) at day 29† 761 595 0.005
PYY postmeal AUC change from baseline assessed at day 29 (pmol/L z h over 3 h) 20.7 6.0* 0.018
Seated systolic blood pressure change from baseline assessed at day 29 (mmHg) 23.9 24.9 0.45
Safety
Patients with any TEAE (%) 12 (71) 14 (88) N/A
Patients with SAE (both with DKA‡) 0 2 N/A
Hypoglycemic events (SMBG #70 mg/dL, baseline–day 36) 354 304 N/A
Documented symptomatic hypoglycemia (SMBG #70 mg/dL, baseline–day 36) 185 162 N/A
Asymptomatic hypoglycemia (SMBG #70 mg/dL, baseline–day 36) 117 80 N/A
SH 0 0 N/A
Hypoglycemia (SMBG #70 mg/dL, PPD) change from baseline at days 3–27 20.4* 20.7* 0.77
Hypoglycemia (CGM $10 continuous min ,70 mg/dL, PPD) change from baseline
assessed at days 3–27 20.15 20.09 0.75
Laboratory values associated with volume status
Serum sodium (mmol/L), change from baseline at day 29 (day 36) 21.00 (20.53) 20.50 (1.50) N/A
Serum creatinine (mmol/L), change from baseline at day 29 (day 36) 20.53 (1.53) 2.63 (0.63) N/A
Serum BUN (mmol/L), change from baseline at day 29 (day 36) 0.41 (0.11) 1.02 (20.41) N/A
Hematocrit, change from baseline at day 29 (day 36) 21.4 (0) 2.1 (1.5) N/A
For laboratory values, change from baseline was assessed at day 29, the last day of therapy, and day 36, 1 week off therapy, unless otherwise
specified. N/A, not applicable; SAE, serious adverse event. *P, 0.05, change from baseline. †Day 1 is not a true “baseline”; therefore, P values are
calculated from two-sample t tests using the observedmeans. ‡Bothwere assessed as due to insulin pump and deemed not drug related. Bold values
are statistically significant.
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dose while improving glycemic control
by multiple measures including lower
mean daily glucose, a higher percentage
of time spent in target range, less time
spent in hyperglycemic ranges, and
lower HbA1c.
Sotagliflozin also produced significant
pre- and postmeal improvements in glu-
cose levels by CGM. Improvement in
postprandial glucose was also demon-
strated by favorable effects during the
MMTT, where compared with placebo,
sotagliflozin produced a statistically sig-
nificant decrease in 3-h plasma glucose
AUC at the end of treatment. The pri-
mary effect of SGLT1 inhibition is reduc-
tion in postprandial glucose (19,29–31)
and, of note, occurred with significantly
lower bolus insulin used by patients on
sotagliflozin. This contrasts with trials of
empagliflozin and dapagliflozin, selec-
tive SGLT2 inhibitors, in type 1 diabetes
that did not show any significant reduc-
tions in bolus insulin use (15,32,33). Fur-
ther work is required to clarify the
extent to which this discrepancy is
driven by the SGLT1 inhibition of sotagli-
flozin versus differences in trial design.
Importantly, the favorable effects on
daily glycemic control and insulin use
were accompanied by a 0.55% reduction
of HbA1c after 29 days of treatment with
sotagliflozin. In an 8-week open-label
study in patients with type 1 diabetes,
empagliflozin produced a 0.4% reduc-
tion in HbA1c (32).
The reduction in bolus insulin use
could contribute to a lower risk for post-
prandial hypoglycemia, and it is inter-
esting to note that hypoglycemic events
PPD were numerically lower than base-
line for both treatment groups when
measured by either SMBG or blinded
CGM. Based on these findings, sotagliflo-
zin provided clinically meaningful im-
provement in glycemic control without
increased hypoglycemic events. Patients
treated with sotagliflozin also demon-
strated significant improvements in
measures of glycemic variability based
on 24-h CGM analysis during the treat-
ment period. These measures included
the 24-h SD, 24-h glucose interquartile
range, HBGI (a predictor for hyperglyce-
mia), mean daily sensor glucose, and
MAGE.
Patients treated with sotagliflozin
demonstrated weight loss (21.7 kg)
compared with a weight gain (0.5 kg)
for the placebo group. The systolic
blood pressure decrease in the sotagli-
flozin group (24.9 mmHg) was similar to
the placebo group (23.9 mmHg). Con-
sistent with the SGLT1 inhibitory effects
of sotagliflozin, postprandial GI hor-
mone PYY was significantly increased
and sotagliflozin’s SGLT2 inhibitor effect
was reflected by increased UGE. These
parameters provide confirmation of so-
tagliflozin’s dual mechanism of action of
SGLT1 inhibition in the GI tract and
SGLT2 inhibition in the kidney.
Four patients in the sotagliflozin
group reported an AE of nausea com-
pared with one patient in the placebo
group, an effect possibly associated
with increased GLP-1 activity. One case
occurred 3 days after cessation of treat-
ment. The three cases that occurred
during treatment were early in onset,
mild in intensity, and of short duration
(2 days or less). No patient on sotagliflozin
reported any genitourinary infections,
while one patient onplacebo reported cys-
titis in theposttreatment follow-upperiod.
There were no cases of SH reported, and
numerically less hypoglycemic events
PPD in the sotagliflozin-treated group
compared with placebo. Two patients in
the sotagliflozin group reported an event
Table 3—Summary of CGM and CGM-derived results and prespecified insulin dose analysis
Placebo (N = 17) Sotagliflozin (N = 16)
PBaseline Treatment
Change from
baseline value [%] Baseline Treatment
Change from
baseline value [%]




1.09 (1.01) 0.90 (0.47) 20.2 [NC] 1.06 (0.59) 0.95 (0.41) 20.1 [NC] 0.75
CGM % time in ranges (mg/dL)
,70 8.5 (9.5) 5.8 (4.7) 22.3 [NC] 7.9 (7.3) 6.7 (5.0) 21.5 [NC] 0.80
70–180 55.9 (12.1) 54.0 (12.0) 20.2 [NC] 56.4 (15.6) 68.2 (12.1)* 11.6 [NC] 0.003
.180 35.6 (14.4) 40.2 (13.7) 2.5 [NC] 35.7 (18.3) 25.0 (11.2)* 210.1 [NC] 0.002
.250 12.0 (9.3) 14.1 (7.9) 1.1 [NC] 15.3 (14.8) 6.7 (6.6)* 27.9 [NC] 0.008
CGM variability measures
SD (mg/dL) 57.2 (13.9) 58.8 (9.6) 1.2 [NC] 60.5 (16.5) 50.0 (12.2)* 28.9 [NC] 0.022
Coefficient of variation 35.6 (8.8) 35.4 (5.2) 0.3 [NC] 37.4 (5.2) 33.7 (6.0) 22.9 [NC] 0.41
MAGE 135.5 (34.9) 145.5 (25.6) 7.5 [NC] 145.5 (39.5) 120.8 (30.5)* 220.0 [NC] 0.041
HBGI 8.7 (3.7) 9.7 (3.7) 0.5 [NC] 9.2 (6.5) 6.2 (3.1)* 22.9 [NC] 0.006
LBGI 2.2 (2.2) 1.5 (1.1)* 20.6 [NC] 1.9 (1.5) 1.8 (1.2) 20.2 [NC] 0.61
Insulin dose data
Total daily bolus (primary) 20.9 (14.0) 18.8 (11.2) 22.1 [26.4] 23.0 (11.6) 15.4 (9.2) 27.3 [232.0] 0.007
Total daily basal 26.1 (9.4) 25.9 (9.3) 20.2 [0.2] 27.1 (7.1) 26.6 (8.7) 20.5 [22.4] 0.53
Total daily (basal + bolus) 45.9 (17.5) 44.4 (15.5) 21.5 [20.7] 47.0 (17.9) 37.6 (15.3) 27.6 [215.3] 0.029
Breakfast bolus 4.8 (4.1) 4.4 (2.9) d [13.6] 5.6 (3.6) 3.4 (2.0) d [228.4] 0.046
Lunch bolus 5.6 (4.8) 5.0 (3.9) d [7.1] 6.4 (3.9) 4.4 (2.7) d [225.9] 0.08
Dinner bolus 6.2 (5.7) 5.8 (4.2) d [39.3] 7.2 (4.1) 5.3 (3.4) d [223.8] 0.052
Data are mean (SD) unless otherwise indicated. Arithmetic change from baseline is shown; P values are from least squares mean analyses of change from
baseline scores (absolute and%change). Thebaseline analysis period consists of days26 to22, and the treatment analysis period consists of days 3–27. LBGI,
low blood glucose index; NC, not calculated. *P , 0.05, change from baseline. Bold values are statistically significant.
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of DKA, which was attributed (by the
investigators) to insulin pump therapy.
Both cases were associated with high lab-
oratory blood glucose readings (.350
mg/dL [19.4 mmol/L]) at presentation, a
finding expected in DKA. Nonetheless,
given the serious nature of such events,
DKAwill be closelymonitored in all future
type 1 diabetes trials. Notably, two cases
of DKA were reported in patients with
type 1 diabetes receiving the selective
SGLT2 inhibitor empagliflozin, but in
both cases the patients presented with
blood glucose levels lower than typically
associated with DKA (14,32).
This initial study of sotagliflozin in type
1 diabetes had several limitations. With
the known effects of sotagliflozin on re-
ducing glucose absorption, bolus insulin
administration was closely monitored in
an inpatient setting during the first 48 h
of the study, and guidance for insulin
dosing upon first dosingwith sotagliflozin
was conservative with an emphasis on
patient safety in an effort to lower the
theoretical risk for episodes of SH. This
could have introduced bias in the results
favoring a reduction of bolus insulin use
compared with basal over the outpatient
treatment period. Finally, highly signifi-
cant reductions in insulin doses achieved
in some patients may have led certain
participants or caregivers to believe
they were effectively unblinded during
the study, introducing behavioral biases
that could have impacted the results
given the small numbers of patients en-
rolled in this study.
Although insulin provides a lifesaving
therapy for individuals with type 1 dia-
betes, the challenges and burden of
managing the disease with insulin ther-
apy alone remain daunting. As work
continues to develop disease-modifying
treatments such as the artificial pancreas,
b-cell transplantation, and immunomod-
ulatory therapy to protect b-cells, efforts
must also be made to identify adjunct
therapies that could be used in combina-
tion with insulin to improve glycemic
control, lower the burden of disease, and
improve quality of life. After 29 days’
treatment, sotagliflozin, a next-generation
dual SGLT1 and SGLT2 inhibitor, signifi-
cantly reduced HbA1c levels, daily bolus
and total daily insulin dose, postprandial
blood glucose, and body weight, with no
increase in hypoglycemia risk. In addition,
sotagliflozin significantly improved time
spent in the glucose range as measured
by the following CGM glucose indices:
mean daily glucose; percent time spent be-
tween 70 and 180 mg/dL, .180 mg/dL,
and .250 mg/dL; and glucose variability
(mean SD, MAGE, and HBGI). Sotagliflozin
as an adjunctive treatment to insulin im-
proved both glucose control and glycemic
variability. Larger studies of a longer dura-
tion are needed to confirm these findings.
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